Nebenwirkungen · Gotenfia
Gotenfia 50 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 11
HOS-153871 · Präparat HOS-101064
Tabulated list of adverse reactions ARs observed in clinical studies and reported from world-wide post-marketing use of golimumab are listed in Table 2. Within the designated system organ classes, the ARs are listed under headings of frequency and using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T14:34:00Z · SHA-256 9ed339171b0daaef4c95efe77e333a813f5a2e0f8a3934c14714714e9cc0cd6e · Passage 1234b072e9bf0ebb1e2e1a2c12d917e838dcc3b8d1ae9b1aa4d60e211736ff07 · Zeichen 687–1262 im Abschnitt